Reinhard Stauder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6699338/publications.pdf

Version: 2024-02-01

111 papers	7,618 citations	147726 31 h-index	53190 85 g-index
115 all docs	115 docs citations	115 times ranked	6485 citing authors

#	Article	IF	Citations
1	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	0.6	2,458
2	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 2007, 110, 4385-4395.	0.6	719
3	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	0.8	584
4	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 2013, 122, 2943-2964.	0.6	567
5	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia Research, 2007, 31, 727-736.	0.4	478
6	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017, 129, 1753-1762.	0.6	278
7	Anemia at older age: etiologies, clinical implications, and management. Blood, 2018, 131, 505-514.	0.6	266
8	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
9	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. Journal of Clinical Oncology, 2011, 29, 1963-1970.	0.8	139
10	Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clinical Interventions in Aging, 2014, 9, 1187.	1.3	111
11	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology, 2014, 93, 1825-1838.	0.8	84
12	Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist, 2014, 19, 1069-1075.	1.9	76
13	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncology, The, 2015, 16, 1506-1514.	5.1	76
14	Validation of the revised international prognostic scoring system (<scp>IPSS</scp>â€R) in patients with lowerâ€risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry. British Journal of Haematology, 2015, 170, 372-383.	1.2	72
15	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia, 2018, 32, 1380-1392.	3.3	66
16	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology, 2018, 29, 544-562.	0.6	64
17	Anemia in the elderly: clinical implications and new therapeutic concepts. Haematologica, 2014, 99, 1127-1130.	1.7	62
18	Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. Journal of Geriatric Oncology, 2015, 6, 141-152.	0.5	61

#	Article	IF	Citations
19	Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. Journal of Geriatric Oncology, 2020, 11, 1190-1198.	0.5	60
20	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research, 2014, 38, 475-483.	0.4	59
21	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. British Journal of Haematology, 2015, 168, 361-370.	1.2	59
22	Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica, 2020, 105, 1484-1493.	1.7	57
23	Azacitidine in patients with WHO-defined AML â€“ Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. Journal of Hematology and Oncology, 2013, 6, 32.	6.9	56
24	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica, 2018, 103, 1593-1603.	1.7	49
25	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica, 2020, 105, 1183-1188.	1.7	46
26	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences, 2017, 18, 415.	1.8	45
27	The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Annals of Hematology, 2012, 91, 1333-1343.	0.8	41
28	Impact of Age and Comorbidity in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 927-934.	2.3	37
29	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. Journal of Hematology and Oncology, 2016, 9, 39.	6.9	36
30	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2020, 105, 632-639.	1.7	35
31	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica, 2020, 105, 640-651.	1.7	32
32	Patientâ€reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 2018, 124, 1251-1259.	2.0	31
33	The cancer patientâ€™s perspective of COVIDâ€19â€induced distressâ€”A crossâ€sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic. Cancer Medicine, 2021, 10, 3928-3937.	1.3	28
34	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. Blood, 2014, 124, 955-955.	0.6	26
35	Aging and blood disorders: new perspectives, new challenges. Haematologica, 2015, 100, 415-417.	1.7	25
36	Patientâ€reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. European Journal of Haematology, 2020, 104, 476-487.	1.1	25

#	Article	IF	Citations
37	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. Journal of Geriatric Oncology, 2014, 5, 299-306.	0.5	24
38	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leukemia and Lymphoma, 2018, 59, 1113-1120.	0.6	23
39	Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. Journal of Geriatric Oncology, 2019, 10, 497-503.	0.5	22
40	Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. Leukemia and Lymphoma, 2007, 48, 1900-1909.	0.6	21
41	PPT and VES-13 in elderly patients with cancer: Evaluation in multidimensional geriatric assessment and prediction of survival. Journal of Geriatric Oncology, 2014, 5, 415-421.	0.5	21
42	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	1.7	20
43	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. Blood, 2011, 118, 2775-2775.	0.6	20
44	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	1.8	19
45	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Advances, 2018, 2, 2079-2089.	2.5	18
46	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). Wiener Klinische Wochenschrift, 2019, 131, 410-418.	1.0	18
47	Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Drugs and Aging, 2015, 32, 891-905.	1.3	15
48	Malnutrition in Older Patients With Hematological Malignancies at Initial Diagnosis â€“ Association With Impairments in Health Status, Systemic Inflammation and Adverse Outcome. HemaSphere, 2020, 4, e332.	1.2	14
49	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 2020, 34, 2451-2459.	3.3	14
50	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. Blood, 2016, 128, 3186-3186.	0.6	14
51	Proposed score for survival of patients with myelodysplastic syndromes. European Journal of Clinical Investigation, 2013, 43, 1120-1128.	1.7	12
52	Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances, 2020, 4, 4029-4044.	2.5	12
53	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Advances, 2021, 5, 3066-3075.	2.5	12
54	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica, 2020, 105, 2516-2523.	1.7	12

#	Article	IF	Citations
55	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Annals of Hematology, 2017, 96, 1105-1112.	0.8	11
56	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemiaâ€"A Retrospective Analysis in 337 Patients. International Journal of Molecular Sciences, 2020, 21, 3025.	1.8	11
57	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. Journal of Geriatric Oncology, 2021, 12, 848-850.	0.5	11
58	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 2021, 137, 31-44.	2.4	11
59	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. Journal of Geriatric Oncology, 2018, 9, 287-290.	0.5	10
60	Development of a core outcome set for myelodysplastic syndromes â€" a Delphi study from the EUMDS Registry Group. British Journal of Haematology, 2020, 191, 405-417.	1.2	10
61	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. European Journal of Haematology, 2021, 107, 265-274.	1.1	10
62	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a <scp>G</scp>erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	1.5	8
63	MRIâ€Based Iron Phenotyping and Patient Selection for Nextâ€Generation Sequencing of Nonâ€"Homeostatic Iron Regulator Hemochromatosis Genes. Hepatology, 2021, 74, 2424-2435.	3.6	8
64	ecancermedicalscience. Ecancermedicalscience, 2014, 8, ed39.	0.6	7
65	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. Clinical Leukemia, 2007, 1, 353-356.	0.2	7
66	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	1.2	7
67	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. Annals of Hematology, 2021, 100, 2921-2932.	0.8	7
68	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. Blood, 2015, 126, 2861-2861.	0.6	7
69	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. Blood Advances, 2021, , .	2.5	6
70	Comorbidities cluster with impaired functional capacities and depressive mood and predict adverse outcome in older patients with hematological malignancies. Leukemia and Lymphoma, 2020, 61, 1954-1964.	0.6	6
71	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. Blood, 2012, 120, 3830-3830.	0.6	6
72	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) â€" AGMT_CMML-1. Leukemia and Lymphoma, 2018, 59, 1121-1126.	0.6	5

#	Article	IF	Citations
73	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. International Journal of Molecular Sciences, 2020, 21, 6057.	1.8	5
74	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry. Blood, 2010, 116, 2917-2917.	0.6	5
75	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. Blood, 2015, 126, 2515-2515.	0.6	5
76	Is Myelodysplasia a Consequence of Normal Aging?. Current Oncology Reports, 2021, 23, 142.	1.8	5
77	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 2018, 67, 21-26.	0.4	4
78	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agentsâ€"A Prospective Cohort Study of the AGMT Study-Group. Cancers, 2022, 14, 2459.	1.7	4
79	Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. Wiener Klinische Wochenschrift, 2013, 125, 50-53.	1.0	3
80	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Expert Review of Hematology, 2018, 11, 109-116.	1.0	3
81	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	1.5	3
82	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers, 2020, 12, 1891.	1.7	3
83	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. Journal of Clinical Medicine, 2020, 9, 1005.	1.0	3
84	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. Blood, 2013, 122, 2770-2770.	0.6	3
85	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. Blood, 2014, 124, 3681-3681.	0.6	3
86	Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?. Blood, 2015, 126, 3742-3742.	0.6	3
87	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. European Journal of Haematology, 2022, , .	1.1	3
88	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 2020, 112, 141-146.	0.7	2
89	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood, 2011, 118, 1715-1715.	0.6	2
90	Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry. Blood, 2012, 120, 700-700.	0.6	2

#	Article	IF	Citations
91	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. Blood, 2014, 124, 2284-2284.	0.6	2
92	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. Blood, 2014, 124, 943-943.	0.6	2
93	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. Blood, 2015, 126, 2554-2554.	0.6	2
94	Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. Blood, 2019, 134, 3821-3821.	0.6	2
95	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. Blood, 2020, 136, 29-29.	0.6	2
96	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. Journal of Geriatric Oncology, 2022, , .	0.5	2
97	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener Klinische Wochenschrift, 2015, 127, 12-15.	1.0	1
98	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. Blood, 2018, 132, 4357-4357.	0.6	1
99	The G8 Screening Tool Detects Relevant Geriatric Impairments and Predicts Survival In Elderly Blood Cancer Patients. Blood, 2013, 122, 5209-5209.	0.6	1
100	A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) â€“ AGMT_CMML 1. Blood, 2014, 124, 3268-3268.	0.6	1
101	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. Blood, 2014, 124, 3683-3683.	0.6	1
102	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	0.6	1
103	Myelodysplastic syndromes (MDS). Memo - Magazine of European Medical Oncology, 2009, 2, 108-109.	0.3	0
104	New developments in MDS. Memo - Magazine of European Medical Oncology, 2012, 5, 186-189.	0.3	0
105	Establishment and validation of aÂnovel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.0	0
106	Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood, 2011, 118, 4266-4266.	0.6	0
107	Myelodysplastic Syndromes in Older Patients. , 2015, , 49-61.		0
108	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. Blood, 2015, 126, 2099-2099.	0.6	0

#	Article	IF	Citations
109	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. Blood, 2015, 126, 1677-1677.	0.6	0
110	High Prevalence and Clinical Impact of Malnutrition in Older Patients with a Hematological Malignancyâ€"Basis for Patient Orientated Guidelines and Healthcare Interventions. Blood, 2018, 132, 3532-3532.	0.6	0
111	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes â€" a Delphi Survey from the European-MDS Registry. Blood, 2018, 132, 2295-2295.	0.6	0